Lv11
70 积分 2025-01-20 加入
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
3天前
已完结
Therapeutic pipeline in nonalcoholic steatohepatitis
4天前
已完结
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
10天前
已完结
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial
10天前
已完结
Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2–F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study
10天前
已完结
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials
10天前
已完结
The pan‐caspase inhibitor Emricasan (IDN‐6556) decreases liver injury and fibrosis in a murine model of non‐alcoholic steatohepatitis
11天前
已完结
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
1个月前
已完结
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
1个月前
已完结
WS10.03 Inhaled LUNAR®-CFTR mRNA (ARCT-032) is safe and well-tolerated: A phase 1 study
1个月前
已完结
皖公网安备34019202002308
